Bacillus subtilis revives conventional antibiotics against Staphylococcus aureus osteomyelitis.
Fan ZhangBowei WangShiluan LiuYuhui ChenYihuang LinZixian LiuXianrong ZhangBin YuPublished in: Microbial cell factories (2021)
As treatment of Staphylococcus aureus (S. aureus) osteomyelitis is often hindered by the development of antibiotic tolerance, novel antibacterial therapeutics are required. Here we found that the cell-free supernatant of Bacillus subtilis (B. subtilis CFS) killed planktonic and biofilm S. aureus, and increased S. aureus susceptibility to penicillin and gentamicin as well. Further study showed that B. subtilis CFS suppressed the expression of the genes involved in adhesive molecules (Cna and ClfA), virulence factor Hla, quorum sensing (argA, argB and RNAIII) and biofilm formation (Ica and sarA) in S. aureus. Additionally, our data showed that B. subtilis CFS changed the membrane components and increased membrane permeabilization of S. aureus. Finally, we demonstrated that B. subtilis CFS increased considerably the susceptibility of S. aureus to penicillin and effectively reduced S. aureus burdens in a mouse model of implant-associated osteomyelitis. These findings support that B. subtilis CFS may be a potential resistance-modifying agent for β-lactam antibiotics against S. aureus.
Keyphrases
- staphylococcus aureus
- biofilm formation
- bacillus subtilis
- pseudomonas aeruginosa
- cell free
- candida albicans
- mouse model
- escherichia coli
- methicillin resistant staphylococcus aureus
- cystic fibrosis
- machine learning
- risk assessment
- small molecule
- binding protein
- gram negative
- big data
- deep learning
- data analysis
- soft tissue
- artificial intelligence
- circulating tumor cells